Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME

This document constitutes regulated information in the sense of the Royal Decree of 14 November 2007 and/or the Law of 2 August 2002. For the full press release, download the PDF document(s) above.